Paxlovid对COVID-19合并冠心病患者的疗效观察和随访研究

郑 阳, 姜 国攀, 刘 双
吉林省人民医院

摘要

背景资料:在2022年3月初,吉林省新型冠状病毒肺炎(COVID-19)疫情大爆发并确定为奥密克戎(Omicron)变异毒株｡2022年3月19日,吉林省人民医院被列为国内首批使用奈玛特韦片/利托那韦片(Paxlovid)抗击COVID-19的医疗单位,用于治疗成人伴有进展为重症高风险因素的轻至中度COVID-19患者｡目的:观察COVID-19合并冠状动脉粥样硬化性心脏病(冠心病)患者使用Paxlovid的临床疗效｡方法:以2022年3月-2023年5月吉林省人民医院收治的COVID-19合并冠心病患者为研究对象｡入组患者分为观察组和对照组｡对照组给予常规治疗用药｡观察组在常规治疗的基础上给予奈玛特韦片150mg/利托那韦片100mg组合包装,每12小时一次口服给药,连续服用5天｡对两组患者在院期间临床资料及出院随访结果进行统计学处理｡以转为重型/危重型的比例为因变量,采用二元Logistic回归分析,P<0.05为差异有统计学意义｡结果:Paxlovid应用于COVID-19合并冠心病患者中转为重型和危重型的比率和再住院率明显降低｡完全接种疫苗可减少转为重型/危重型比率｡合并非稳定性冠心病､高血压､糖尿病,心力衰竭､慢性肺病､肾脏疾病､肝脏疾病患者更容易转为重型/危重型｡结论:COVID-19合并冠心病患者应用Paxlovid转为重型/危重型的比率明显降低｡另外,高血压,糖尿病,心力衰竭,慢性肺病,肾脏疾病,肝脏疾病,疫苗次数与患者预后相关｡

关键词

Paxlovid;COVID-19;冠心病;Omicron变异株

参考

[1]LaiCC,ShihTP,KoWC,etal.Se-vereacuterespiratorysyndromecoronavirus2(SARS-CoV-2)andcoronavirusdisease-2019(COVID-19):Theepidemicandthechallenges.IntJAntimicrobAgents2020;55(3),105924.[2]WorldHealthOrganization.COVID-19Situationreport-51.2020.[3]HammondJ,Leister-TebbeH,GardnerA,etal.EPIC-HRInvestigators.Oralnir¬matrelvirforhigh-risk,nonhospitalizedadultswithCovid-19.NEnglJMed2022;386:1397–408.[4]USFoodandDrugAdministration.Factsheetforhealthcareproviders:emergen¬cyauthorizationforPaxlovid.2022.Availableat:https://www.fda.gov/media/155050/download.Accessed30April2022.[5]PfizerInc.Pfizerannouncesadditionalphase2/3studyresultsconfirmingrobustefficacyofnovelCOVID-19oralantiviraltreatmentcandidateinreducingriskofhospitalizationordeath.2021.[6]MahaseE.Covid-19:Pfizer'sPaxlovidis89%effectiveinpatientsatriskofseriousillness,companyreports.BMJ2021;375:n2713.[7]WorldHealthOrganization.UpdateonOmicron.November28,2021.[8]FDA.Factsheetforhealthcareproviders:emergencyuseau⁃thorizationforPaxlovidTM[EB/OL].(2021-12-22)[2022-02-13].[9]PuhachO,AdeaO,AdeaK,etal.Infectiousviralloadinunvaccinatedandvaccinatedindividualsinfectedwithancestral,DeltaorOmicronSARS-CoV-2[J].NatMed,2022,28(7):1491-1500.[10]WolfelR,CormanVM,GuggemosW,etal.VirologicalassessmentofhospitalizedpatientswithCOVID-2019[J].Nature,2020,581(7809):465-469.[11]ChanJWM,NgCK,ChanYH,etal.Shorttermoutcomeandriskfactorsforadverseclinicaloutcomesinadultswithsevereacuterespiratorysyndrome(SARS)[J].Thorax,2003,58(8):686-689.[12]BadawiA,RyooSG.PrevalenceofcomorbiditiesintheMiddleEastrespiratorysyndromecoronavirus(MERS-CoV):asystematicreviewandmeta-analysis[J].IntJ.[13]ZhouF,YuT,DuR,etal.ClinicalcourseandriskfactorsformortalityofadultinpatientswithCOVID-19inWuhan,China:aretrospectivecohortstudy[J].Lancet,2020,395(10229):1054-1062.[14]WangD,HuB,HuC,etal.Clinicalcharacteristicsof138hospitalizedpatientswith2019novelcoronavirus-infectedpneumoniainWuhan,China[J].JAMA,2020,2(2020-02-07)[2020-04-06].[15]GuanW,NiZ,HuY,etal.Clinicalcharacteristicsofcoronavirusdisease2019inChina[J].NEnglJMed,2020,382(18):1708-1720.[16]HuH,MaF,WeiX,etal.Coronavirusfulminantmyocarditissavedwithglucocorticoidandhumanimmunoglobulin[J].EurHeartJ,2020,(2020-03-16)[2020-04-08].[17]SalaS,PerettoG,GramegnaM,etal.AcutemyocarditispresentingasareverseTako-TsubosyndromeinapatientwithSARSCoV-2respiratoryinfection[J]EurHeartJ,2020,4(2020-04-08)[2020-04-10].